Comparison of sitagliptin, glimepiride, and metformin group with glimepiride and metformin group in treatment of diabetes mellitus type 2 patients

Abstract

Objective: To compare glycaemia control between glimepiride and metformin group with sitagliptin, glimepiride and metformin group in uncontrolled type 2 diabetic patient.
Methods: This retrospective, randomized, clinical study was done in the diabetes research center. The number of the patient in this study was thirty-five patients. The patients examined individually in detail to check their general health in addition to the physical state. For all the patients, data had been collected and fasting plasma glucose level had been measured. Participants have been chosen by unresponsiveness of diabetic patient to single therapy of metformin or glimepiride in this trial. The patients were allocated into 2 groups. Group I include 14 patient given glimepiride, metformin and sitagliptin, while group II include 21 patients given glimepiride and metformin. Both groups continue treatment for thirty days and statistical analyses include data collection was done.
Results: A statistical significant decrease was found in fasting plasma glucose level when compare before and after treatment regimen of sitagliptin, Glimepiride and Metformin group while no significant difference in fasting plasma glucose when comparing the triple therapy group (Sitagliptin, Glimepiride and Metformin) with the double therapy group (Glimepiride and Metformin) after thirty days of treatment.
Conclusion: No significant difference was found between glimepiride and metformin therapy with sitagliptin, glimepiride and metformin therapy in uncontrolled type 2 diabetic patient.